Biogen (BIIB) is a leading biotech company in Boston. Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders.
Biogen (BIIB) is a leading biotech company in Boston. Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders.
For the next 5 years, Biogen Inc. is expecting Growth of 8.93% per annum.
The company shows its Return on Assets (ROA) value of 18.5%.
The Return on Equity (ROE) value stands at 36%.
While it’s Return on Investment (ROI) value is 23.5%.
Read at
https://www.newsoracle.com/2017/01/10/research-report-for-biogen-inc-nasdaqbiib-2/
3 Reasons Biogen Inc. Stock Is Set to Soar in 2017
Read at
http://www.fool.com/investing/2016/12/20/3-reasons-biogen-inc-stock-is-set-to-soar-in-2017.aspx
PE = 17 currently.
Biogen has steady growth in the past years and the coming years.
The valuate at about 17 is reasonable.
The stock prices start to rise with the biotech sector.
Buy.